Opinion Article - Virology Research Journal (2023) Volume 7, Issue 3

Antiviral approaches targeting viral gene expression in infected cells

Department of Biology, FAU, Erlangen, Germany

*Corresponding Author:

Amanda Jared
Department of Biology
FAU, Erlangen, Germany
E-mail: amanda@fau.de

Received: 24-Apr-2023, Manuscript No. AAVRJ-23-97705; Editor assigned: 25-Apr-2023, PreQC No. AAVRJ-23-97705(PQ); Reviewed: 09-May-2023, QC No. AAVRJ-23-97705; Revised: 16-May-2023, Manuscript No. AAVRJ-23-97705(R); Published: 23-May-2023, DOI:10.35841/AAVRJ-7.3.141

Citation: Jared A. Antiviral approaches targeting viral gene expression in infected cells. Virol Res J. 2023;7(3):141

Introduction

Viral gene expression is a complex process that is essential for the replication of viruses. In order to produce new viral particles, viruses need to hijack the host cell's machinery to synthesize viral proteins and replicate their genetic material. Because of this dependence on the host cell, targeting viral gene expression has become a promising approach in the development of antiviral therapies. In this article, we will discuss the different antiviral approaches that target viral gene expression in infected cells. Transcription factors are essential proteins that bind to DNA sequences and regulate the transcription of specific genes. In the case of viral gene expression, viruses have evolved to produce their own transcription factors that interact with host transcription factors to regulate viral gene expression. Targeting these viral transcription factors is an attractive approach for antiviral therapy, as it can inhibit the expression of multiple viral genes simultaneously. For example, the HIV-1 Tat protein is an essential transcription factor for viral gene expression, and several drugs have been developed that specifically target Tat [1].

RNA polymerase is an enzyme that catalyzes the synthesis of RNA from a DNA template. Viruses require RNA polymerase for the transcription of their genetic material. Inhibiting RNA polymerase activity can therefore be an effective way to prevent viral gene expression [2]. For example, the nucleoside analogue drug ribavirin has been used to inhibit the RNA polymerase activity of the hepatitis C virus. Once viral RNA has been synthesized, it needs to be translated into viral proteins. Translation initiation is the process by which ribosomes bind to mRNA and initiate protein synthesis. Inhibition of translation initiation can prevent the synthesis of viral proteins, and therefore the production of infectious virions. For example, drugs that target the eukaryotic translation initiation factor eIF4E have been shown to inhibit the translation of several different viruses, including hepatitis C and respiratory syncytial virus. Many viruses produce their own proteases that cleave viral proteins into functional units. Targeting these viral proteases can prevent the proper processing of viral proteins and disrupt viral gene expression. For example, protease inhibitors have been developed for the treatment of hepatitis C and HIV infections. RNA interference is a process by which small RNA molecules can be used to target and degrade specific mRNA molecules. RNA interference can be used to specifically target viral mRNA, preventing the synthesis of viral proteins and disrupting viral gene expression. Several RNA interference-based therapies have been developed for the treatment of hepatitis B and C infections.

In conclusion, targeting viral gene expression in infected cells is an attractive approach for the development of antiviral therapies. By inhibiting viral transcription, RNA polymerase activity, translation initiation, viral proteases, or using RNA interference, the production of infectious virions can be disrupted, and viral replication can be inhibited. Although many antiviral therapies that target viral gene expression are currently available, there is still a need for the development of new and more effective therapies to combat viral infections. Viral infections are a significant global health problem, and the development of antiviral therapies is critical to combating them. Viruses have evolved several mechanisms to evade the host immune response, replicate within host cells, and persist in infected individuals. One crucial aspect of viral replication is the expression of viral genes, which is tightly regulated and essential for the production of viral proteins necessary for viral replication and assembly. As such, targeting viral gene expression represents a promising approach for the development of novel antiviral therapies.

One approach to targeting viral gene expression is by inhibiting viral RNA polymerase, the enzyme responsible for catalyzing the synthesis of viral RNA. The inhibition of viral RNA polymerase has been shown to be effective against several viral infections, including influenza and hepatitis C. The antiviral drug, sofosbuvir, is an RNA polymerase inhibitor that has shown significant efficacy against hepatitis C virus (HCV). Sofosbuvir is a nucleoside analog that acts as a chain terminator, preventing the synthesis of viral RNA. Several other nucleoside analogs have also been developed, including remdesivir, which has shown efficacy against several viruses, including Ebola virus, respiratory syncytial virus, and SARSCoV- 2 [3-5].

Another approach to targeting viral gene expression is by inhibiting viral proteins essential for viral replication. This strategy involves the use of small molecule inhibitors, peptides, or monoclonal antibodies to disrupt the function of viral proteins. For example, the HIV-1 integrase inhibitor, raltegravir, blocks the integration of the viral genome into the host cell DNA. Similarly, the hepatitis B virus (HBV) replication inhibitor, entecavir, targets the viral reverse transcriptase, preventing the synthesis of viral DNA. Additionally, monoclonal antibodies targeting viral proteins have been developed, such as the monoclonal antibody, palivizumab, which targets the respiratory syncytial virus (RSV) fusion protein. Viruses rely on the host cell machinery for the processing of viral RNA. Interfering with this process represents another approach to targeting viral gene expression. For example, the splicing inhibitor, pladienolide B, has been shown to inhibit the splicing of viral RNA in cells infected with influenza virus, preventing viral replication. Similarly, the RNA helicase inhibitor, quercetin, has been shown to inhibit the replication of several RNA viruses by blocking viral RNA synthesis. Viral gene expression relies on the host cell machinery for transcription and translation. Targeting host factors involved in viral gene expression represents a promising strategy for the development of antiviral therapies. One example is the development of inhibitors targeting the host cell protease, furin, which is involved in the processing of the SARS-CoV-2 spike protein.

References

1. Sayers TJ. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J Immunol.1998;161:3957-65.

Indexed at, Google Scholar, Cross Ref

2. Wang Z.RING-H2 protein WSSV249 from white spot syndrome virus sequesters a shrimp ubiquitin-conjugating enzyme, PvUbc, for viral pathogenesis. J Virol.2005;79:8764-72.

Indexed at, Google Scholar, Cross Ref

3. T. Taniguchi, Takaoka A. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623-55.

Indexed at, Google Scholar, Cross Ref

4. Huang J, Huang Q. The poxvirus p28 virulence factor is an E3 ubiquitin ligase. J Biol Chem.2004; 279: 54110-16.

Indexed at, Google Scholar, Cross Ref

5. Jung SJ. Does heavy oil pollution induce bacterial diseases in Japanese flounder Paralichthys olivaceus. Mar Pollut Bull. 2008;57:889-94.

Indexed at, Google Scholar, Cross Ref